An Artificial Intelligence-Augmented Conversational Agent to Improve Cancer Care

DESCRIPTION
We are collaborating with the Penn Medicine Health Care Innovation Center to develop and evaluate an AI-augmented conversational agent — also known as a chat bot — to enhance oral chemotherapy adherence, reduce unplanned hospitalizations and emergency department visits, and provide more efficient lines of communications between clinicians and patients.

IMPACT
This study is currently in progress. Early learnings and evidence of success informed a funded initiative in lung cancer.

PEOPLE
Lawrence Shulman, MD; Michael Serpa, MS; Bethany Mooney, MSN, CRNP, Oncology Nurse Practitioner at the Abramson Cancer Center; Christine Cambareri, PharmD, BCPS, BCOP, Oncology Clinical Pharmacist at the Abramson Cancer Center; Sam Takvorian, MD; Katharine Rendle, PhD, MSW, MPH; Justin Bekelman, MD; and Roy Rosin, MBA.

ABSTRACT
Leveraging a Conversational Agent to Support Adherence to Oral Anticancer Agents: A Usability Study

PARTNERS
The Penn Medicine Health Care Innovation Center and Patient.ly

FOCUS
Augmented & Artificial Intelligence
Behavior Change Incentives
Clinical Transformation